Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Cardiff Oncology Inc (NASDAQ: CRDF) closed at $4.16 down -9.17% from its previous closing price of $4.58. In other words, the price has decreased by -$9.17 from its previous closing price. On the day, 1.0 million shares were traded. CRDF stock price reached its highest trading level at $4.5 during the session, while it also had its lowest trading level at $4.01.
Ratios:
For a deeper understanding of Cardiff Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.74 and its Current Ratio is at 4.74. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.Robert W. Baird initiated its Outperform rating on December 08, 2021, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 276740672 and an Enterprise Value of 156735392. For the stock, the TTM Price-to-Sale (P/S) ratio is 401.03 while its Price-to-Book (P/B) ratio in mrq is 4.10. Its current Enterprise Value per Revenue stands at 227.813 whereas that against EBITDA is -3.407.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.72, which has changed by 1.6321838 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $6.42, while it has fallen to a 52-week low of $1.63. The 50-Day Moving Average of the stock is 10.86%, while the 200-Day Moving Average is calculated to be 38.35%.
Shares Statistics:
For the past three months, CRDF has traded an average of 2.07M shares per day and 1013320 over the past ten days. A total of 66.52M shares are outstanding, with a floating share count of 62.51M. Insiders hold about 6.02% of the company’s shares, while institutions hold 27.72% stake in the company. Shares short for CRDF as of 1738281600 were 10451856 with a Short Ratio of 4.57, compared to 1735603200 on 9507049. Therefore, it implies a Short% of Shares Outstanding of 10451856 and a Short% of Float of 16.02.
